33 results
Our main goal is to establish whether there is difference in the effect between the use of aspirin, dualtherapy aspirin/clopidogrel, or ticagrelor on the occurrence of atherothrombotic events in patients following lower extremity peripheral…
The objective of the proposed study is to evaluate if results as are written above, are to be extrapolated on high risk patients who underwent vascular surgery. In this group of patients, there is a substantial risk of 15-20% to die in the first…
Primary Objective: to obtain reliable estimates of the rates of vascular death and non-fatal stroke in patients with atrial fibrillation and a recent anticoagulation-associated ICH who are treated with apixaban versus those who are treated with APDs…
Primary Objective:The primary objective is to demonstrate the efficacy of 1 or 2 dose regimens of HZN-825 versus placebo in subjects with diffuse cutaneous SSc, as determined by a comparison of change in forced vital capacity (FVC) % predicted after…
A real world registry to compare dual therapy with Dabigatran/Clopidogrel to Usual care (Triple Therapy) with Dabigatran/Clopidogrel/Aspirin in patients with an indication for NOAC undergoing PCI in the setting of ACS. Hypothesis: Dual therapy with…
The primary aim of the GENPAD study is to evaluate the ability of genotype-guided antithrombotic treatment to reduce adverse clinical events related to arterial thrombosis in patients with peripheral arterial disease. Secondary aims are to evaluate…
To evaluate if an individualized antithrombotic P2Y12-inhibitor monotherapy in comparison to an individualized DAPT treatment is superior regarding bleeding events and non-inferior regarding ischemic events in patient with CCS after PCI.
The purpose of this study is to see if Crinecerfont is effective in reducing daily glucocorticoid dosage while maintaining adrenal androgen control.The purpose of the study is also to see if Crinecerfont is effective in reducing adrenal steroid…
To determine if clopidogrel treatment can be optimized in patients with a low or high BW/BMI compared to patients with a normal BW by adjusting the dosage of clopidogrel and evaluating platelet reactivity measured using the VerifyNow.
To assess whether the in-laboratory strategy is non-inferior to the preloading strategy in patients planned for diagnostic CAG with optional ad-hoc PCI.
The aim of this study is to evaluate the feasibility and safety of CYP2C19-genotype-guided p2y12 inhibitor selection in patients who are indicated for (D)OAC and require PCI. Both safety and efficacy outcomes will be captured. Also a cost-benefit…
Core phase: The overall objective of the core phase is to investigate the efficacy, safety and tolerability of 2 dose regimens of HZN-825, a selective antagonist of lysophosphatidic acid receptor-1 (LPAR1), administered once daily (QD) or twice…
To assess whether and to what extent dual therapy clopidogrel 75 mg/acetylsalicylic acid 80 mg daily is superior to monotherapy clopidogrel 75 mg daily, in reducing the combined endpoint all-cause death and cardiovascular adverse events after one-…